Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 6/20 | 0.60 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.60 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.60 |
| ▸ | CD209 | Q9NNX6 | 2/20 | 0.50 |
| ▸ | ENGASE | Q8NFI3 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | CD69 | Q07108 | 1/20 | 0.48 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.47 |
| ▸ | AMY2A | P04746 | 2/20 | 0.47 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.47 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.43 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17148009 | 1.00 | LGALS3 (0.60) | LGALS3LGALS8LGALS4CD209ENGASE | |
| SCHEMBL29540408 | 1.00 | LGALS3 (0.60) | LGALS3LGALS8LGALS4CD209ENGASE | |
| SCHEMBL17148015 | 1.00 | LGALS3 (0.60) | LGALS3LGALS8LGALS4CD209ENGASE | |
| SCHEMBL30110520 | 1.00 | LGALS3 (0.60) | LGALS3LGALS8LGALS4CD209ENGASE | |
| SCHEMBL29419069 | 1.00 | LGALS3 (0.60) | LGALS3LGALS8LGALS4CD209ENGASE | |
| SCHEMBL29694256 | 0.98 | LGALS3 (0.59) | LGALS3LGALS8LGALS4CD209ENGASE | |
| SCHEMBL29370195 | 0.97 | LGALS3 (0.57) | LGALS3LGALS8LGALS4CD209ENGASE | |
| SCHEMBL29532287 | 0.97 | LGALS3 (0.61) | LGALS3LGALS8LGALS4CD209ENGASE | |
| SCHEMBL31154034 | 0.96 | LGALS3 (0.56) | LGALS3LGALS8LGALS4CD209ENGASE | |
| SCHEMBL30943987 | 0.96 | LGALS3 (0.56) | LGALS3LGALS8LGALS4CD209ENGASE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 409 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747630-A1 | USE OF THE GLYCANS AS SENESCENT CELL SURFACE MARKERS | Loughborough University (GB) | 2026-05-27 | — | — | EP | claimed |
| EP-4747629-A2 | APOPTOSIS DETECTION | Loughborough University (GB) | 2026-05-27 | — | — | EP | claimed |
| US-20260022192-A1 | RECOMBINANT OLIGOSACCHARYLTRANSFERASES AND METHODS OF USE THEREOF | UNIV CORNELL (US) | 2026-01-22 | — | — | US | claimed |
| US-20250281626-A1 | MANNOSE 3 GLYCAN-MEDIATED PROTEIN DEGRADATION | GLYCOERA AG (CH) | 2025-09-11 | — | — | US | claimed |
| US-12410456-B2 | Cell-free glycoprotein synthesis (CFGPS) in prokaryotic cell lysates enriched with components for glycosylation | NORTHWESTERN UNIVERSITY (US) | 2025-09-09 | — | — | US | claimed |
| US-20250066746-A1 | COMPOSITIONS AND METHODS FOR SOLUBILIZING GLYCOSYLTRANSFERASES | CORNELL UNIVERSITY | 2025-02-27 | — | — | US | claimed |
| WO-2025017322-A2 | APOPTOSIS DETECTION | LOUGHBOROUGH UNIVERSITY (GB) | 2025-01-23 | — | — | WO | claimed |
| WO-2025017323-A1 | USE OF THE GLYCANS AS SENESCENT CELL SURFACE MARKERS | LOUGHBOROUGH UNIVERSITY (GB) | 2025-01-23 | — | — | WO | claimed |
| EP-4453233-A1 | ALPHA-1 ANTITRYPSIN PRODUCED FROM YEAST FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | AATEC Medical GmbH (DE) | 2024-10-30 | — | — | EP | claimed |
| CN-118434880-A | Use of alpha-1 antitrypsin produced by yeast for the treatment of viral infections | AA科技医疗有限公司 | 2024-08-02 | — | — | CN | claimed |
| WO-2023133283-A1 | COMPOSITIONS AND METHODS FOR SOLUBILIZING GLYCOSYLTRANSFERASES | CORNELL UNIVERSITY (US) | 2023-07-13 | — | — | WO | claimed |
| WO-2023118424-A1 | ALPHA-1 ANTITRYPSIN PRODUCED FROM YEAST FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | AATEC MEDICAL GMBH (DE) | 2023-06-29 | — | — | WO | claimed |
| EP-4190817-A1 | ANTI-MUC16 ANTIBODIES AND USES THEREOF | Memorial Sloan Kettering Cancer Center (US) | 2023-06-07 | — | — | EP | claimed |
| US-20230159972-A1 | CELL-FREE GLYCOPROTEIN SYNTHESIS (CFGPS) IN PROKARYOTIC CELL LYSATES ENRICHED WITH COMPONENTS FOR GLYCOSYLATION | CORNELL UNIVERSITY | 2023-05-25 | — | — | US | claimed |
| EP-3205351-B1 | LYSOSOMAL STORAGE DISEASE ENZYME | ALEXION PHARMA INC (US) | 2023-04-12 | — | — | EP | claimed |
| US-20220340947-A1 | PROKARYOTE-BASED CELL-FREE SYSTEM FOR THE SYNTHESIS OF GLYCOPROTEINS | UNIV CORNELL (US) | 2022-10-27 | — | — | US | claimed |
| WO-2022221163-A1 | SOLID-PHASE GLYCAN REMODELING OF GLYCOPROTEINS | MERCK SHARP & DOHME LLC (US) | 2022-10-20 | — | — | WO | claimed |
| WO-2022200388-A1 | MANNOSE 3 GLYCAN-MEDIATED PROTEIN DEGRADATION | GLYCOERA AG (CH) | 2022-09-29 | — | — | WO | claimed |
| US-20220242970-A1 | GLYCAN-BASED ANTIBODY-DRUG CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2022-08-04 | — | — | US | claimed |
| EP-4010470-A1 | FUSION PROTEIN FOR REMODELING ANTIBODY GLYCOFORM | Cho Pharma Inc (TW) | 2022-06-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281626-A1 | MANNOSE 3 GLYCAN-MEDIATED PROTEIN DEGRADATION | MAN2A1, MANBA, MAN2B1 | LGALS3 21/4885LGALS8 46/4885LGALS4 35/4885 |
| US-20260022192-A1 | RECOMBINANT OLIGOSACCHARYLTRANSFERASES AND METHODS OF USE THEREOF | OSTC, OGT, GALNT1 | LGALS3 1506/4885LGALS8 2121/4885LGALS4 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.